CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Coverage Criteria for Prescription Oral Iron Capsules (Iron Deficiency Anemia)

Defines medical necessity criteria and authorization rules for prescription oral iron capsules for adults with iron deficiency anemia for Neighborhood Health Plan of Rhode Island members.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyCoverage Criteria for Prescription Oral Iron Capsules (Iron Deficiency Anemia)

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization with documentation of age ≥18, diagnosis of iron deficiency, required labs (Hb ≤11 g/dL, ferritin ≤100 ng/mL, TSAT <20%), and failure/intolerance to ≥2 oral iron products.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

18+minimum patient age for approval

Hb ≤11hemoglobin threshold

Ferritin ≤100; TSAT <20%iron studies required

≥2 failuresprior therapies required

6 monthsauthorization duration

60/30dquantity limit

Coverage Criteria for Oral Iron Capsules

Initial Therapy

Covered when ALL of the following are met

Initial approval criteria: A. Patient is 18 years or older;

Initial approval criteria: B. Documented diagnosis of iron deficiency;

Initial approval criteria: C. Iron‑deficiency anemia with Hemoglobin (Hb) ≤ 11 g/dL;Hb ≤ 11 g/dL

Iron studies: C.a Ferritin ≤ 100 ng/mL;

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyCoverage Criteria for Prescription Oral Iron Capsules (Iron Deficiency Anemia)

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Clinical Thresholds and Key Values

inv-03: Hemoglobin (Hb) — numeric threshold to support diagnosis

Hemoglobin (Hb) threshold≤11 g/dL

ContextRequired as part of documented iron‑deficiency anemia for authorization

Applies toAdults (age ≥18) per initial approval criteria

inv-04: Ferritin — numeric threshold to support diagnosis

Ferritin threshold≤100 ng/mL

RoleSupports diagnosis of iron‑deficiency anemia when paired with low Hb and TSAT

DocumentationMust be documented in prior authorization request

inv-05: Transferrin saturation (TSAT) — numeric threshold to support diagnosis

Transferrin saturation (TSAT) threshold<20%

UseRequired alongside Hb and ferritin to confirm iron‑deficiency anemia

NotationListed as Transferrin saturation (TSAT) < 20% in approval criteria

Authorization, Step Therapy, and Documentation Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required. Approvals may be granted for up to 6 months with a quantity limit of 2 capsules per day (60 capsules per 30 days).

Approval duration: 6 months
Quantity limit: 2 capsules per day (60 capsules per 30 days)

Step Therapy

Step Therapy Requirement

Step therapy requires documented failure, contraindication, or intolerance to at least two oral iron products (for example, ferrous gluconate, ferrous sulfate).

Required step: failure, contraindication, or intolerance to ≥2 oral iron products

Documentation Required

Documentation Requirements

Documentation must include patient age (≥18 years), diagnosis of iron deficiency, hemoglobin level, ferritin, transferrin saturation (TSAT), and prior therapy history supporting step criteria.

Required: patient age ≥18
Required: documented diagnosis of iron deficiency
Required labs: Hemoglobin ≤11 g/dL, Ferritin ≤100 ng/mL, TSAT <20%
Required: prior therapy history showing trials of ≥2 oral iron products

Denial Risk

Triggers for Denial

Denial may be issued if required elements are missing or criteria are not met.

Patient under 18 years of age (age <18)
Missing documented diagnosis of iron deficiency
Hemoglobin >11 g/dL
Ferritin >100 ng/mL or TSAT ≥20%
No documentation of failure, contraindication, or intolerance to ≥2 oral iron products

Background

Iron deficiency anemia is characterized by low hemoglobin with supportive iron studies and is typically managed first with oral iron therapy. This policy uses clinical and laboratory criteria to define candidates for prescription oral iron capsules: patients must be adults (age ≥18) with a documented diagnosis of iron deficiency and laboratory evidence consistent with iron‑deficiency anemia, specifically Hemoglobin (Hb) ≤11 g/dL with supportive iron studies (Ferritin ≤100 ng/mL and Transferrin saturation (TSAT) <20%).

Oral iron products are first‑line therapy; this coverage policy addresses situations where at least two standard oral iron products (for example, ferrous gluconate or ferrous sulfate) have failed, been contraindicated, or were not tolerated. When the documented clinical and laboratory criteria are met, prior authorization may be approved for a limited duration — typically 6 months — with an outpatient dispensing limit of 2 capsules per day (60 capsules per 30 days).

OpenPayer

Coverage Criteria for Prescription Oral Iron Capsules (Iron Deficiency Anemia)

Coverage Criteria for Oral Iron Capsules

Clinical Thresholds and Key Values

Authorization, Step Therapy, and Documentation Requirements

Background

Definitions